Practical aspects on the diagnosis and treatment of adult mastocytosis;Aspectos practicos sobre el diagnostico y tratamiento de las mastocitosis del adulto

Actas Dermo-Sifiliograficas

Volumn 90, Issue 5, 1999, Pages 211-223

  Escribano, Luis ^b   Bravo, Pilar ^b   Cantalapiedra, Alberto ^b   Carnero, Rosario Vázquez ^b   Gárate, María T ^b   Agustín, Beatriz Díaz ^b   Torrelo, Antonio ^b   Navarro, Lourdes ^b   Zambrano, Antonio ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NONE

Author keywords

Diagnosis; Review; Systemic mast cell disease; Treatment

Indexed keywords

ALPHA INTERFERON; HISTAMINE; LEUKOTRIENE; PROSTAGLANDIN D2;

ADULT; BONE MARROW EXAMINATION; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; MEDIATOR RELEASE; PATIENT EDUCATION; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; SYSTEMIC MASTOCYTOSIS; TREATMENT INDICATION;

EID: 0032968917     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Ehrlich P. Beiträge zur Kenntniss der granulierten Bindegewebszellen und der Eosinophilen Leukocyten. Arch Anat Physiol 1879;3:166-9.
2. Nettleship J, Tay W. Rare forms of urticaria. Br Med J 1869;2:323-4.
3. Ellis J. Urticaria pigmentosa: a report of a case of autopsy. Arch Pathol 1949;48:426-35.
4. Kitamura Y. Shimada M, Hatanaka K, Miyano Y. Development of mast cells from grafted bone marrow cells in irradiated mice. Nature 1977;268:442-3.
5. Kitamura Y, Kanakura Y, Fujita J, Nakano T. Differentiation and transdifferentiation of mast cells: a unique member of the hematopoietic cell family. Int J Cell Cloning 1987;5:108-21.
6. Yarden Y, Ruang WJ, Yang Feng T y cols. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-51.
7. Qiu FH, Ray P, Brown K y cols. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase familyoncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988;7:1003-11.
8. Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 1991;78:30-7.
9. Ogawa M, Matsuzaki Y, Nishikawa S y cols. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 1991;174:63-71.
10. Papayannopoulou T, Bice M, Broudy VC, Zsebo KM. Isolation of c-kit receptor expressing cells from bone marrow, peripheral blood, and fetal liver: functional properties and composite antigenic profile. Blood 1991;78:1403-12.
11. Yamaguchi Y, Gunji Y, Nakamura M y cols. Expression of c-kit mRNA and protein during the differentiation of human hematopoietic progenitor cells. Exp Hematol 1993;21:1233-8.
12. Reisbach G, Bartke I, Kempkes B y cols. Characterization of hemopoietic cell populations from human cord blood expressing c-kit. Exp Hematol 1993;21:74-9.
13. Cambareri AC, Ashman LK, Cole SR, Lyons AB. A monoclonal antibody to a human mast cell/myeloid leukaemia-specific antigen binds to normal haemopoietic progenitor cells and inhibits colony formation in vitro. Leuk Res 1988;12:929-39.
14. Valent P, Ashman LK, Hinterberger W y cols. Mast cell typing: Demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989;73:1778-85.
15. Valent P, Majdic O, Maurer D, Bodger M, Muhm M, Bettelheim P. Further characterization of surface membrane structures expressed on human basophils and mast cells. Int Arch Allergy Appl Immunol 1990;91:198-203.
16. Krilis SA, Warneford SG, Macpherson J y cols. Establishment in culture and characterization of a strain with mast cell and monocytic properties from the bone marrow of a child with diffuse cutaneous mastocytosis. Blood 1991; 78:290-303.
17. Matsui Y, Zsebo KM, Hogan BL. Embryonic expression of a haematopoietic growth factor encoded by the S1 locus and the ligand for c-kit. Nature 1990;347:667-9.
18. Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM. Expression of the c-kit receptor in hypomelanosis: A comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol 1995; 132:182-9.
19. Anderson DM, Lyman SD, Baird A y cols. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms [published erratum appears in Cell 1990 nov 30;63(5):following 1112]. Cell 1990;63:235-43.
20. Huang E, Nocka K, Beier DR y cols. The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63:225.
21. Williams DE, Eisenman J, Baird A y cols. Identification of a ligand for the c-kit proto-oncogene. Cell 1990;63:167-74.
22. Zsebo KM, Williams DA, Geissler EN y cols. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63:213-24.
23. Valent P. The riddle of the mast cell: kit(CD117)-Ligand as the missing link. Immunol Today 1994;15:111-4.
24. Andrews RG, Knitter GH, Bartelmez SH y cols. Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. Blood 1991;78:1975-80.
25. Bernstein ID, Andrews RG, Zsebo KM. Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+ lin-cells, and the generation of colony-forming cell progeny from CD34+lin cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 1991;77:2316-21.
26. Broxmeyer HE, Cooper S, Lu L y cols. Effect of marine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood 1991;77:2142-9.
27. Carow CE, Hangoc G, Cooper SH, Williams DE, Broxmeyer HE. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replacing potential. Blood 1991;78:2216-21.
28. McNiece IK, Langley KE, Zsebo KM. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991;19: 226-31.
29. Avraham H, Scadden DT, Chi S, Broudy VC, Zsebo KM, Groopman JE. Interaction of human bone marrow fibroblasts with megakaryocytes: role of the c-kit ligand. Blood 1992;80:1679-84.
30. Avraham H, Vannier E, Cowley S y cols. Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood 1992;79:365-71.
31. Galli SJ, Tsai M, Wershil BK. Regulation of mast cell proliferation, maturation and function by stem cell factor, a ligand for the c-kit receptor. Int Arch Allergy Immunol 1992;99:234-7.
32. Ratajezac MZ, Luger SM, Gewirtz AM. The c-kit proto-oncogene in normal and malignant human hematopoiesis. Int J Cell Cloning 1992;10:205-14.
33. Abboud MR, Xu F, Payne A, Laver J. Effects of recombinant human Steel factor (c-kit ligand) on early cord blood hematopoietic precursors. Exp Hematol 1994;22:388-92.
34. Verfaillie C, Hurley R, Bhatia R, McCarthy JB. Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit Rev Oncol Hematol 1994;16:201-24.
35. Keller JR, Ortiz M, Ruscetti FW. Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division. Blood 1995;86:1757-64.
36. Ishizaka K, Ishizaka T. Immunoglobulin E. Byosinthesis and immunological mechanism of IgE-mediated hypersensitivity. En: Cellular, molecular and clinical aspects of allergic disorders. Gupta L, Good M, eds. New York: Plenum Press, 1979;153-78.
37. Galli SJ. New concepts about the mast cell. N Engl J Med 1993;328:257-65.
38. Escribano LM, Villa E, Gabriel L y cols. The fine structural localization of endogenous and exogenous peroxidase activity in human bone marrow mast cells under pathological conditions. Histochemistry 1990;93:279-85.
39. Dvorak AM, Klebanoff SJ, Henderson WR, Monahan RA, Pyne K, Galli SJ. Vesicular uptake of eosinophil peroxidase by guinea pig basophils and by cloned mouse mast cells and granule-containing lymphoid cells. Am J Pathol 1985;118:425-38.
40. Longley J. Is mastocytosis a mast cell neoplasia or a reactive hyperplasia? Clues from the study of mast cell growth factor. Ann Med 1994;26:115-6.
41. Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease J Am Acad Dermatol 1995;32:545-61.
42. Longley BJ, Jr., Morganroth GS, Tyrrell L y cols. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993;328:1302-7.
43. Longley BJ, Tyrrell L, Lu SZ y cols. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nature Genet 1996;12:312-4.
44. Piao XH, Bernstein A. A point mutation in the catalytic domain of c-kif induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996;87:3117-23.
45. Nagata H, Okada T, Worobec AS, Semere T, Metcalfe DD. c-kit mutation in a population of patients with mastocytosis. Int Arch Allergy Immunol 1997;113:184-6.
46. Pignon JM, Giraudier S, Duquesnoy P y cols. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997;96:374-6.
47. Pignon JM. C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors. Hematol Cell Ther 1997;39:114-6.
48. Nagata H, Worobec AS, Semere T, Metcalfe DD. Elevated expression of the proto-oncogene c-kit in patients with mastocytosis. Leukemia 1998;12:175-81.
49. Horny HP, Ruck P, Krober S, Kaiserling E. Systemic mast cell disease (mastocytosis). General aspects and histopathological diagnosis. Histol Histopathol 1997;12:1081-9.
50. Kröber SM, Horny HP, Ruck P y cols. Mastocytosis: Reactive or neoplaslic? J Clin Pathol 1997;50:525-7.
51. Longley BJ, Tyrrell L, Lu S, Ma Y, Klump V, Murphy GF. Chronically KIT-stimulated clonally-derived human mast cells show heterogeneity in different tissue microenvironments. J Invest Dermatol 1997;108:792-6.
52. Henz BM. SCF and c-kit in mastocytosis - a Pandora's box holding more theories than proven facts-. J Invest Dermatol 1998;110:186-186.
53. Longley BJ. SCF and c-kit in mastocytosis - a Pandora's box holding more theories than proven facts-Reply. J Invest Dermatol 1998;110:186-7.
54. Roberts LJ, II, Oates JA. Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol 1991;96:19S-25S.
55. Travis WD, Li CY, Su WP. Adult-onset urticaria pigmentosa and systemic mast cell disease. Am J Clin Pathol 1985;84:710-4.
56. Katsuda S, Okada Y, Oda Y, Tanimoto K, Takabatake S. Systemic mastocytosis without cutaneous involvement. Acta Pathol Jpn 1987;37:167-77.
57. Tharp MD, Glass MJ, Seelig LL. Ultrastructural morphometric analysis of lesional skin: mast cells from patients with systemic and nonsystemic mastocytosis. J Am Acad Dermatol 1988;18:298-306.
58. Kirshenbaum AS, Kettelhut BV, Metcalfe DD, Garriga MM. Mastocylosis in infants and children: recognition of patterns of skin disease. Allergy Proc 1989;10:17-21.
59. Irani AA, Garriga MM, Metcalfe DD, Schwartz LB. Mast cells in cutaneous mastocytosis: Accumulation of the MCTC type. Clin Exp Allergy 1990;20:53-8.
60. Soter NA. The skin in mastocytosis. J Invest Dermatol 1991;96:32S-8S.
61. Mackey S, Pride HB, Tyler WB. Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UV-A. Arch Dermatol 1996;132:1429-30.
62. Parker RI, Metcalfe DD. Systemic mastocytosis. En: Hematology. Huffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. New York: Churchill Livingstone, 1995;1399-414.
63. Golkar L, Bernhard JD. Mastocytosis. Lancet 1997;349:1379-85.
64. Escribano L, Orfao A, Villarrubia J y cols. Expression of lymphoid-associated antigens in mast cells: Report of a case of systemic mast cell disease. Br J Haematol 1995;91:941-3.
65. Horny HP, Parwaresch MR, Lennert AK. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985;16:808-14.
66. Ridell B, Olafsson JH, Roupe G y cols. The bone marrow in urticaria pigmentosa and systemic mastocytosis. Cell composition and mast cell density in relation to urinary excretion of tele-methylimidazoleacetic acid. Arch Dermatol 1986;122:422-7.
67. Horny HP, Kaiserling E. Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: a histological and immunohistological study. Br J Haematol 1988;69:149-55.
68. Parker RI. Hematologic aspects of mastocytosis: I: Bone marrow pathology in adult and pediatric systemic mast cell disease. J Invest Dermatol 1991;96:47S-51S.
69. Brunning RD, McKenna RW. Lesions simulating lymphonia and miscellaneous tumor-like lesions in the bone marrow. En: Tumors of the bone marrow. Rosai J, Sobin LH, eds. Washington: Armed Forces Institute of Pathology, 1994;409-37.
70. Webb TA, Li CY, Yam LT. Systemic mast cell disease: A clinical and hematopathologic study of 26 cases. Cancer 1982;49:927-38.
71. Escribano I., Villarrubia J, Cerveró C, Bellas C. Mastocitosis sistémica. Clasificación, clínica, diagnóstico y tratamiento. Medicine 1996;7:1367-72.
72. Travis WD, Li CY, Hoagl HC, Travis LB, Banks PM. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986;61:957-66.
73. Escribano L, Orfao A, Villarrubia J y cols. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997;30:98-102.
74. Parwaresch MR, Horny HP, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985;179:439-61.
75. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine 1988;67:345-68.
76. Topar G, Siaudacher C, Geisen K y cols. Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. Am J Clin Pathol 1998;109:279-85.
77. Orfao A, Escribano L, Villarrubia J y cols. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996;149:1493-9.
78. Escribano L, Orfao A, Villarrubia J y cols. Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples. An Cell Pathol 1998;16:151-9.
79. Escribano L, Orfao A, Díaz Agustín B y cols. Indolent systemic mast cell disease in adults, immunophenotypic characterization and its diagnostic implications. Blood 1997;91:2731-6.
80. Haney K, Russell W, Raila FA, Brewer AC, Harrison RB. MRI characteristics of systemic mastocytosis of the lumbosacral spine. Skeletal Radiol 1996;25:171-3.
81. McKenna MJ, Frame B. The mast cell and bone. Clin Orthop 1985;226-33.
82. Grardel B, Hardouin P. Mastocytosis and bone manifestations. Results of the survey of the bone and phosphorus-calcium metabolism section of the French Society of Rheumatology) Mastocytose et manifestations osseuses. Resultat de l'enquete de la section os et metabolisme phospho-calcique de la Societe Francaise de Rhumatologie. Rev Rhum Mal Osteoartic 1992;59:57-63.
83. Andrew SM, Freemont AJ. Skeletal mastocytosis. J Clin Pathol 1993;46:1033-5.
84. Delsignore JL, Dvoretsky PM, Hicks DG, O'Keefe RJ, Rosier RN. Mastocytosis presenting as a skeletal disorder. Iowa Orthop J 1996;16:126-34.
85. Johansson C, Roupe G, Lindstedt G, Mellstrom D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1996;25:1-7.
86. Biarese V, Raviolo P, Cesarani F, Lobetti L. (Systemic mastocytosis: a case with diffuse bone involvement) Mastocitosi sistemica: un caso con diffuso coinvolgimento osseo. Minerva Med 1996;87:33-9.
87. Rafii M, Firooznia H, Golimbu C, Balthazar E. Pathologic fracture in systemic mastocytosis. Radiographic spectrum and review of the literature. Clin Orthop 1983;260-7.
88. Schoenaers P, De Clerck LS, Timmermans U, Stevens WJ. Systemic mastocytosis, an unusual cause of osteoporosis. Clin Rheumatol 1987;6:458-62.
89. Harvey JA, Anderson HC, Borek D, Morris D, Lukert BP. Osteoporosis associated with mastocytosis confined to bone: report of two cases. Bone 1989;10:237-41.
90. Lidor C, Frisch B, Gazit D, Gepstein R, Hallel T, Mekori YA. Osteoporosis as the sole presentation of bone marrow mastocytosis. J Bone Miner Res 1990;5:871-6.
91. Chines A, Pacifici R, Avioli LV, Teitelbaum SL, Korenblat PE. Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study. J Clin Endocrinol Metab 1991;72:140-4.
92. Floman Y, Amir G. Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. J Spinal Disord 1991;4:369-73.
93. McKenna MJ. Histomorphometric study of mast cells in normal bone, osteoporosis, and mastocytosis using a new stain. Calcif Tissue Int 1994;55:257-9.
94. Teramoto S, Matsuse T, Ouchi Y. Increased production of TNF-□ may play a role in osteoporosis in cystic fibrosis patients. Chest 1997;112:574-574.
95. Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997;99:155-60.
96. Horny H-P, Kaiserling E, Parwaresch MR, Lennert K. Lymph node findings in generalized mastocytosis. Histopathology 1992;21:439-46.
97. Mican JM, Di Bisceglie AM, Fong TL y cols. Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. Hepatology 1995;22:1163-70.
98. Horny H-P, Ruck MT, Kaiserling E. Spleen findings in generalized mastocytosis: A Clinicopathologic study. Cancer 1992;70:459-68.
99. Miner PB, Jr. The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Invest Dermatol 1991;96:40S-4S.
100. Cherner JA, Jensen RT, Dubois A, O'Dorisio TM, Gardner JD, Metcalfe DD. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988;95:657-67.
101. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991;96:5S-13S.
102. Austen KF. Systemic mastocytosis. N Engl J Med 1992; 326:639-40.
103. Tharp MD. Mast cell disease and its diagnosis. J Invest Dermatol 1995;104:885-6.
104. Mutter RD, Tannenbaum M, Ultman JE. Systemic mast cell disease. Ann Intern Med 1963;59:887-906.
105. Metcalfe DD. Clinical advances in mastocytosis: an interdisciplinary roundtable discussion. J Invest Dermatol 1991;96:supl. 1S-65S.
106. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988;62:965-72.
107. Yoo D, Lessin LS, Jensen WN. Bone-marrow mast cells in lymphoproliferative disorders. Ann Intern Med 1978;88:753-7.
108. Prokocimer M, Polliack A. Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders. Am J Clin Pathol 1981;75:34-8.
109. Yoo D, Lessin LS. Bone marrow mast cell content in preleukemic syndrome. Am J Med 1982;73:539-42.
110. Eberlein-König B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy 1995;25:704-12.
111. Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997;100:458-63.
112. Elberink JNGO, De Monchy JGR, Kors JW, Van Doormaal JJ, Dubois AEJ. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997;99:153-4.
113. Greenblatt EP, Chen L. Urticaria pigmentosa: An anesthetic challenge. J Clin Anesth 1990;2:108-15.
114. Stellato C, De Paulis A, Cirillo R, Mastronardi P, Mazzarella B, Marone G. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991;74:1078-86.
115. Marone G, Stellato C. Activation of human mast cells and basophils by general anaesthetic drugs. Monogr Allergy 1992;30:54-73.
116. Stellato C, Marone G. Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Chem Immunol 1995;62:108-31.
117. Genovese A, Stellato C, Marsella CV, Adt M, Marone G. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Int Arch Allergy Immunol 1996;110:13-22.
118. Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 1998;80:26-9.
119. Ojeda A, Crespo A, Crespo V, Sánchez F, Sanz A, Vera A. Telangiectasia maculosa eruptiva persistente con afectacion sistémica y evolución postoperatoria fatal. Actas Dermosifiliogr 1996;87:539-42.
120. Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997;350:1115-6.
121. Zhang MQ. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 1997;4:171-84.
122. Coulie P, Delaere A, De Vos C, Donnelly F, Rihoux JP. Non-sedating antihistamines and cardiac arrhythmias. Lancet 1998;351:451-451.
123. Delgado LF, Pferferman A, Solé D, Naspitz CK. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998;80:333-7.
124. Godt O, Proksch E, Streit V, Christophers E. Short-and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997;195:35-9.
125. Friedman B, Darling G, Norton J, Hamby L, Metcalfe D. Splenectomy in the management of systemic mast cell disease. Surgery 1990;107:94-100.
126. Kluin-Nelemans HG, Jansen JH, Breukelman H y cols. Response to interferon ALFA-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619-23.
127. Czarnetzki BM, Algermissen B, Jeep S y cols. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 1994;30:500-1.
128. Harrison BD, Ashford RA, Hatten CSR. Case report: Systemic mastocytosis - A case treated with interferon □ and radiotherapy. Clin Lab Haematol 1994;16:291-4.
129. Delaporte E, Piérard E, Wolthers BG y cols. Interferon-□ in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995;132:479-82.
130. Fiehn C, Prümmer O, Gallati H, Heilig B, Hunstein W. Treatment of systemic mastocytosis with interferon-gamma: Failure after appearance of anti-IFN-gamma antibodies. Eur J Clin Invest 1995;25:615-8.
131. Granerus G, Lönnqvist B, Roupe G. Histamine metabolism in mastocytosis patients treated with interferon □-2b. Inflamm Res 1996;45:S41-S3.
132. Kolde G. Long-term effect of interferon alpha treatment in mastocytosis. Reply Br J Dermatol 1996;134:1165-1165.
133. Lippert U, Henz BM. Long-term effect of interferon alpha treatment in mastocytosis. Br J Dermatol 1996;134:1164-5.
134. Worobec AS, Kirshenbaum AS, Schwanz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996;22:501-8.
135. Hübner C, Wedding U, Strater J, Limberg B, Stremmel W. Clinical stable systemic mastocytosis with interferon alpha-2b therapy. J Intern Med 1997;241:529-33.
136. Butterfield JH. Response of severe systemic mastocytosis to Interferon alpha. Br J Dermatol 1998;138:489-95.
137. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alfa-2-Interferon. Acta Haematol 1995;85:220-220.
138. Prümmer O, Fiehn C, Gallati H. Anti-interferon-gamma antibodies in a patient undergoing interferon-gamma treatment for systemic mastocytosis. J Interferon Cytokine Res 1996;16:519-22.
139. Galli SJ, Dvorak HF. Basophils and mast cells. Structure, function, and role in hypersensitivity. En: Cellular, molecular and clinical aspects of allergic diseases. Gupta L, Good M, eds. New York: Plenum Press, 1979;1-53.
140. Oertel HL, Kaliner M. The biologic activity of mast cell granules. III. Purification of inflammatory factors of anaphylaxis (IF-A) responsible for causing late-phase reactions. J Immunol 1981;127:1398-402.
141. Galli SJ, Dvorak AM. What do mast cells have to do with delayed hypersensitivity. Lab Invest 1984;50:365-8.
142. Nadel JA. Roles of mast cell proteases in airways. Drugs 1989;37Supl: 1:51-5.
143. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-□/cachectin. Nature 1990;346:274-6.
144. Peters SP. Mast cells and histamine in asthma. J Allergy Clin Immunol 1990;86 Supl: 642-6.
145. Nadel JA. Biologic effects of mast cell enzymes. Am Rev Respir Dis 1992; 145 Supl: S37-S41.
146. Galli SJ. Seminars in medicine of the Beth Israel Hospital, Boston: New concepts about the mast cell. N Engl J Med 1993;328:257-65.
147. Marshall JS, Bienenstock J. The role of mast cells in inflammatory reactions of the airways, skin and intestine. Curr Opin Immunol 1994;6:853-9.
148. Schwartz L.B. Mast cells: Function and contents. Curr Opin Immunol 1994;6:91-7.
149. Galli SJ, Wershil BK. Immunology the two faces of the mast cell. Nature 1996;381:21-2.